Controlling Health Care Costs Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? Issue Briefs / Oct 05, 2017
Controlling Health Care Costs The Case for Drug-Pricing Reform — The Cost of Inaction blog / May 26, 2021
Controlling Health Care Costs External Reference Pricing: The Drug-Pricing Reform America Needs? Issue Briefs / May 27, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs blog / Aug 18, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid Blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs Blog / Aug 18, 2021
Controlling Health Care Costs Competition, Consolidation, and Evolution in the Pharmacy Market Issue Briefs / Aug 12, 2021
Controlling Health Care Costs The Role of Pharmacies in Making Drug Purchasing More Efficient and in Promoting Access to Preventive Care Issue Briefs / Aug 12, 2021
Controlling Health Care Costs Biden’s Executive Order Promotes Competition to Lower Drug Costs Blog / Jul 30, 2021
Controlling Health Care Costs External Reference Pricing: The Drug-Pricing Reform America Needs? Issue Briefs / May 27, 2021
Controlling Health Care Costs The Case for Drug-Pricing Reform — The Cost of Inaction Blog / May 26, 2021
Controlling Health Care Costs Federal Antitrust Tools Are Inadequate to Prevent Anticompetitive Health Care Consolidation Blog / May 13, 2021
Controlling Health Care Costs House Oversight Committee’s Investigations into Drug Pricing Highlight Need for Reform Blog / Apr 30, 2021
